---
layout: post
title: "Request for Public Comment on NIOSH Initial Recommendations To Change the Status of Liraglutide and Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings"
date: 2026-02-05 18:53:10 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-00693
original_published: 2024-01-16 00:00:00 +0000
significance: 8.00
---

# Request for Public Comment on NIOSH Initial Recommendations To Change the Status of Liraglutide and Pertuzumab on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings

**Published:** February 05, 2026 18:53 UTC
**Source:** Federal Register
**Original Published:** January 16, 2024 00:00 UTC
**Document Number:** 2024-00693

## Summary

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services (HHS), requests public comment on two draft reevaluations with initial recommendations to change the status of two drugs, liraglutide and pertuzumab, on the NIOSH List of Antineoplastics and Other Hazardous Drugs in Healthcare Settings (List). The reevaluations were developed based on the process described in the NIOSH Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings. Based on the reevaluations, the NIOSH initial recommendations are to remove liraglutide and pertuzumab from the List.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/01/16/2024-00693/request-for-public-comment-on-niosh-initial-recommendations-to-change-the-status-of-liraglutide-and)
- API: https://www.federalregister.gov/api/v1/documents/2024-00693

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
